RESUMO
Adult rheumatoid arthritis (RA) is a very heterogeneous disease that is associated with HLA-antigens, although no absolute association has been found with any particular HLA type. Forty-one seropositive RA patients have been studied with a local monoclonal antibody named X1 21.4 (9w940), strongly associated with HLA-DRI, DR4, Drw10 antigens, to verify a possible correlation with the disease. The results obtained have also been compared with the data reported on MC1, a serologically defined determinant correlated with RA. X1 21.4 monoclonal antibody appears to be associated with the disease and it could identify one epitope involved in the susceptibility to RA.
Assuntos
Anticorpos Monoclonais , Artrite Reumatoide/imunologia , Antígenos HLA , Adulto , Epitopos , Antígenos HLA-DR , Antígeno HLA-DR1 , Antígeno HLA-DR4 , HumanosAssuntos
Artrite Reumatoide/tratamento farmacológico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Prednisona/uso terapêutico , Pregnenodionas/uso terapêutico , Adolescente , Adulto , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Pessoa de Meia-Idade , Prednisona/administração & dosagem , Pregnenodionas/administração & dosagem , Equivalência TerapêuticaAssuntos
Artrite Juvenil/imunologia , Antígenos HLA/classificação , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , MasculinoAssuntos
Anti-Inflamatórios/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Rigidez Muscular/tratamento farmacológico , Propionatos/uso terapêutico , Adulto , Idoso , Anti-Inflamatórios/administração & dosagem , Compostos de Bifenilo/administração & dosagem , Compostos de Bifenilo/uso terapêutico , Avaliação de Medicamentos , Feminino , Humanos , Indometacina/uso terapêutico , Pessoa de Meia-Idade , Fenilbutiratos , Propionatos/administração & dosagemRESUMO
Cartilage and bone marrow extracts have been used to enhance cartilage mucopolysaccharide levels. The value of this form of treatment was appraised in 250 groups of 250 patients with well established arthrosis. Comparison was made between standard management with anti-inflammatory drugs, analgesics, anti-rheumatic compounds, physiotherapy and heat treatment, and management with the addition of cartilage and bone marrow extracts (Arumalon) over a period of 5 yr. Patients who received Arumalon had a lower frequency of painful exacerbations, a lower and more delayed frequency of functional incapacity, and a slower and less striking radiological progression. These results corroborate experimental and clinical data in the literature. They were particularly marked in 50 cases of gonarthrosis.